Pharmacists in Jenison, Michigan


29 Pharmacists found in Jenison
female pharmacist

Dr. Kathleen S. Mcmillan, PHARMD


Pharmacist
334 Chicago Dr, Jenison, MI 49428
616-457-2730     616-457-2730

female pharmacist

Dr. Kathryn Marie Dudzinski, PHARM.D.


Pharmacist
550 Baldwin St, Jenison, MI 49428
616-667-4607    

male pharmacist

Dr. Keith M Wright Ii, PHARMD


Pharmacist
550 Baldwin St, Jenison, MI 49428
616-667-2010    



male pharmacist

Mr. Mark Knowlton, PHARM.D.


Pharmacist
334 Chicago Dr, T-0399, Jenison, MI 49428
616-457-2730     616-457-2730

male pharmacist

Martin Robert Kugel Jr, RPH


Pharmacist
1965 Baldwin St, Jenison, MI 49428
616-457-9630     616-457-1120

female pharmacist

Michelle A Young


Pharmacist
3150 Park South Dr, Jenison, MI 49428
616-669-4970    

male pharmacist

Dr. Quintin Andrew Hacker, PHARMD


Pharmacist
550 Baldwin St, Jenison, MI 49428
616-667-2010    

female pharmacist

Rachael Bell, PHARMD, RPH


Pharmacist
550 Baldwin St, Jenison, MI 49428
201-061-6667    

female pharmacist

Ms. Ramona June Zimmerman, RPH


Pharmacist
378 Baldwin St, Jenison, MI 49428
616-667-8695    

female pharmacist

Regan Vanderveen


Pharmacist
550 Baldwin St, Jenison, MI 49428
616-667-2010    

male pharmacist

Roger Dejonge


Pharmacist
550 Baldwin St, Jenison, MI 49428
616-667-2033     616-667-2065

female pharmacist

Dr. Sarah Kathryn Marston, PHARM.D


Pharmacist - Pharmacotherapy
550 Baldwin St, Jenison, MI 49428
616-667-2010    

male pharmacist

Mr. Scott Edward Sorensen, R.PH.


Pharmacist
1965 Baldwin St, Jenison, MI 49428
616-457-9630    


Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.